Here, we analysed Aire deficiency on C57BL/6 background in presymptomatic and postsymptomatic phases, which could shed light into the design and development of future clinical trials in patients with APS-1. This evidence concerns the gene AIRE and autoimmune polyendocrine syndrome type 1.